Mechanism for the differentiation of EoL-1 cells into eosinophils by histone deacetylase inhibitors

被引:8
作者
Kaneko, Motoko
Ishihara, Kenji
Takahashi, Aki
Hong, JangJa
Hirasawa, Noriyasu
Zee, OkPyo
Ohuchi, Kazuo
机构
[1] Tohoku Univ, Grad Sch Pharmaceut Sci, Lab Pathophysiol Biochem, Aoba Ku, Sendai, Miyagi 9808578, Japan
[2] Sungkyunkwan Univ, Grad Sch Pharm, Lab Pharmacognosy, Suwon, South Korea
[3] Sookmyung Womens Univ, Coll Pharm, Lab Pathophysiol, Seoul, South Korea
[4] Yasuda Womens Univ, Fac Pharm, Hiroshima, Japan
关键词
EoL-1; cells; eosinophils; differentiation; histone deacetylase inhibitors; FIP1L1; PDGFRA;
D O I
10.1159/000101401
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
Background: EoL-1 cells have a FIP1L1-PDGFRA fusion gene which causes the transformation of eosinophilic precursor cells into leukemia cells. Recently, we suggested that the induction of differentiation of EoL-1 cells into eosinophils by the HDAC inhibitors apicidin and n-butyrate is due to the continuous inhibition of HDACs. However, neither apicidin nor n-butyrate inhibited the expression of FIP1L1-PDGFRA mRNA, although both these inhibitors suppressed cell proliferation. Therefore, in this study, we analyzed whether the levels of FIP1L1-PDGFR alpha protein and phosphorylated-Stat5 involved in the signaling for the proliferation of EoL-1 cells are attenuated by HDAC inhibitors. Methods: EoL-1 cells were incubated in the presence of apicidin, TSA or n-butyrate. FIP1L1-PDGFR alpha and phosphorylated-Stat5 were detected by Western blotting. Results: Treatment of EoL-1 cells with apicidin at 100 nM or n-butyrate at 500 M decreased the levels of FIP1L1-PDGFR alpha protein and phosphorylated-Stat5, while that with trichostatin A at 30 nM did not. Conclusions: The decrease in the level of FIP1L1-PDGFR alpha protein caused by apicidin and n-butyrate might be one of the mechanisms by which EoL-1 cells are induced to differentiate into eosinophils by these HDAC inhibitors. Copyright (C) 2007 S. Karger AG, Basel.
引用
收藏
页码:28 / 32
页数:5
相关论文
共 26 条
[1]   Epigenetics and airways disease [J].
Adcock, IM ;
Ford, P ;
Ito, K ;
Barnes, PJ .
RESPIRATORY RESEARCH, 2006, 7 (1)
[2]   Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90 - A novel basis for antileukemia activity of histone deacetylase inhibitors [J].
Bali, P ;
Pranpat, M ;
Bradner, J ;
Balasis, M ;
Fiskus, W ;
Guo, F ;
Rocha, K ;
Kumaraswamy, S ;
Boyapalle, S ;
Atadja, P ;
Seto, E ;
Bhalla, K .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2005, 280 (29) :26729-26734
[3]   The EOL-1 cell line as an in vitro model for the study of FIP1L1-PDGFRA-positive chronic eosinophilic leukemia [J].
Cools, J ;
Quentmeier, H ;
Huntly, BJP ;
Marynen, P ;
Griffin, JD ;
Drexler, HG ;
Gilliland, DG .
BLOOD, 2004, 103 (07) :2802-2805
[4]   A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome [J].
Cools, J ;
DeAngelo, DJ ;
Gotlib, J ;
Stover, EH ;
Legare, RD ;
Cortes, J ;
Kutok, J ;
Clark, J ;
Galinsky, I ;
Griffin, JD ;
Cross, NCP ;
Tefferi, A ;
Malone, J ;
Alam, R ;
Schrier, SL ;
Schmid, J ;
Rose, M ;
Vandenberghe, P ;
Verhoef, G ;
Boogaerts, M ;
Wlodarska, I ;
Kantarjian, H ;
Marynen, P ;
Coutre, SE ;
Stone, R ;
Gilliland, DG .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (13) :1201-1214
[5]   ON THE BIOLOGICAL ROLE OF HISTONE ACETYLATION [J].
CSORDAS, A .
BIOCHEMICAL JOURNAL, 1990, 265 (01) :23-38
[6]   Apicidin: A novel antiprotozoal agent that inhibits parasite histone deacetylase [J].
DarkinRattray, SJ ;
Gurnett, AM ;
Myers, RW ;
Dulski, PM ;
Crumley, TM ;
Allocco, JJ ;
Cannova, C ;
Meinke, PT ;
Colletti, SL ;
Bednarek, MA ;
Singh, SB ;
Goetz, MA ;
Dombrowski, AW ;
Polishook, JD ;
Schmatz, DM .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (23) :13143-13147
[7]   Inhibition of histone deacetylase activity by butyrate [J].
Davie, JR .
JOURNAL OF NUTRITION, 2003, 133 (07) :2485S-2493S
[8]   Histone deacetylases (HDACs): characterization of the classical HDAC family [J].
De Ruijter, AJM ;
Van Gennip, AH ;
Caron, HN ;
Kemp, S ;
Van Kuilenburg, ABP .
BIOCHEMICAL JOURNAL, 2003, 370 :737-749
[9]   Clinical development of histone deacetylase inhibitors as anticancer agents [J].
Drummond, DC ;
Noble, CO ;
Kirpotin, DB ;
Guo, ZX ;
Scott, GK ;
Benz, CC .
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 2005, 45 :495-528
[10]   Discovery of a fusion kinase in EOL-1 cells and idiopathic hypereosinophilic syndrome [J].
Griffin, JH ;
Leung, J ;
Bruner, RJ ;
Caligiuri, MA ;
Briesewitz, R .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (13) :7830-7835